LLY

922.05

+3.3%↑

JNJ

244.49

+1.14%↑

ABBV

218.67

+2.76%↑

NVS

152.63

+1.82%↑

MRK

120.98

+0.01%↑

LLY

922.05

+3.3%↑

JNJ

244.49

+1.14%↑

ABBV

218.67

+2.76%↑

NVS

152.63

+1.82%↑

MRK

120.98

+0.01%↑

LLY

922.05

+3.3%↑

JNJ

244.49

+1.14%↑

ABBV

218.67

+2.76%↑

NVS

152.63

+1.82%↑

MRK

120.98

+0.01%↑

LLY

922.05

+3.3%↑

JNJ

244.49

+1.14%↑

ABBV

218.67

+2.76%↑

NVS

152.63

+1.82%↑

MRK

120.98

+0.01%↑

LLY

922.05

+3.3%↑

JNJ

244.49

+1.14%↑

ABBV

218.67

+2.76%↑

NVS

152.63

+1.82%↑

MRK

120.98

+0.01%↑

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

5.01

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.01

Max

5.01

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.3M -3M
Verkäufe	100K 100K
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-208K 39M
Vorheriger Eröffnungskurs	5.01
Vorheriger Schlusskurs	5.01

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. März 2026, 23:15 UTC

Wichtige Nachrichtenereignisse

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30. März 2026, 22:36 UTC

Wichtige Nachrichtenereignisse

Australian Government Rules Out Boots on the Ground in the Middle East

30. März 2026, 22:13 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30. März 2026, 21:00 UTC

Ergebnisse

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30. März 2026, 20:15 UTC

Wichtige Nachrichtenereignisse

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30. März 2026, 23:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. März 2026, 23:40 UTC

Market Talk

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30. März 2026, 23:36 UTC

Market Talk

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30. März 2026, 23:12 UTC

Market Talk

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30. März 2026, 22:49 UTC

Market Talk

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30. März 2026, 22:44 UTC

Market Talk

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30. März 2026, 22:43 UTC

Market Talk

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30. März 2026, 22:42 UTC

Market Talk

South32 Should Go for Growth, Says New Bull -- Market Talk

30. März 2026, 22:18 UTC

Market Talk

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30. März 2026, 22:05 UTC

Market Talk

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30. März 2026, 21:58 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Life Financial Agrees to Buy Bell Partners for $350M

30. März 2026, 21:39 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30. März 2026, 21:38 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30. März 2026, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30. März 2026, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30. März 2026, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30. März 2026, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30. März 2026, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30. März 2026, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30. März 2026, 21:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. März 2026, 21:25 UTC

Market Talk

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30. März 2026, 21:03 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30. März 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. März 2026, 20:09 UTC

Ergebnisse

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30. März 2026, 20:00 UTC

Wichtige Nachrichtenereignisse

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.